ArticleAmerican journal of translational research2025
Clinical efficacy and predictive indicators of cindilizumab combined with XELIRI protocol in advanced colorectal carcinoma patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the therapeutic efficacy of adding cindilizumab to the Xeloda-Irinotecan (XELIRI) regimen in patients with advanced colorectal cancer and to identify clinical and molecular biomarkers predictive of treatment response.
methodsA retrospective analysis was conducted on 197 patients with advanced colorectal carcinoma treated between January 2019 and June 2023. Patients were divided into two cohorts: the standard treatment group receiving XELIRI alone (n=103) and the combined treatment group receiving XELIRI with cindilizumab (n=94). Treatment response was assessed according to RECIST criteria and classified as responsive (complete response [CR] or partial response [PR]) or non-responsive (stable disease [SD] or progressive disease [PD]). Logistic regression analysis was performed to identify independent predictors of treatment response. Adverse events were recorded throughout the treatment course.
resultsThe experimental cohort demonstrated statistically higher objective response rate (ORR) and disease control rate (DCR) compared to the standard treatment cohort (ORR: 38.30% versus 22.33%, P=0.015; DCR: 80.85% versus 66.02%, P=0.019). The incidence of hypothyroidism and renal impairment was significantly higher in the combination group (P=0.002). Logistic regression identified carcinoembryonic antigen (CEA) (OR=1.336, P<0.001), tumor diameter (OR=2.818, P=0.001), KRAS/NRAS gene status (OR=6.229, P=0.001), and treatment regimen (OR=0.079, P<0.001) as independent predictors of treatment response. Receiver operating characteristic (ROC) curve analysis showed that their combined prediction significantly improved predictive efficacy (AUC=0.881), with high sensitivity and specificity.
conclusionCindilizumab combined with XELIRI regimen improves ORR and DCR in patients with advanced colorectal cancer but may increase the risk of hypothyroidism and renal impairment. CEA, tumor diameter, KRAS/NRAS gene, and treatment regimen are independent predictors of treatment response. The combined predictive model demonstrates robust diagnostic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.